Skip to main content
TipRanks
Go Ultimate75% OFF

Acrux (FJY) AI Stock Analysis

0 Followers
DE:FJY

Acrux

(Frankfurt:FJY)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
2026 Revenue ReboundRevenue rebounded by about 65% in 2026 after sharp declines, restoring commercial scale and demonstrating that Acrux’s business can regain demand. If sustained, this recovery could improve operating leverage and provide a stronger base for funding product development.
Negative Factors
Persistent UnprofitabilityPersistent net, EBIT, and EBITDA losses show that Acrux has not yet established a sustainable profit engine. Ongoing unprofitability can consume financial resources, limit internally funded investment, and make future performance highly dependent on successful commercialization.

Acrux (FJY) vs. iShares MSCI Germany ETF (EWG)

Not enough price history over this period.

Market Cap
EUR 2.41M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-7.1
Beta (1Y)
1.23
Revenue Growth
292.45%
EPS Growth
91.51%
Country
Germany
Employees
43
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Acrux Business Overview & Revenue Model

Company Description

Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international...

Acrux Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:FJY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:CUVAU:CUV77OutperformAUD 365.53M10.5713.00%0.69%-1.05%-6.74%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:TRPAU:TRP50NeutralAUD 5.86M-1.24-52.04%―32.22%-26.53%
AU:SPLAU:SPL44NeutralAUD 200.41M-23.98-42.35%―145.32%25.75%
AU:CMBAU:CMB39UnderperformAUD 10.30M-1.39-247.44%―-4.24%33.39%
AU:BOTAU:BOT38UnderperformAUD 27.63M-0.28-118.74%―499.47%31.20%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%AU:CUVAU:SPLAU:TRPAU:CMBAU:BOTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:FJY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:FJYAcrux Limited―――
AU:CUVClinuvel Pharmaceuticals Limited7.24-3.74-34.08%
AU:SPLStarpharma Holdings Limited0.410.049.50%
AU:TRPTissue Repair Ltd0.11-0.18-62.07%
AU:CMBRegeneus Ltd.0.35-0.17-32.69%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.11-91.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.